Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (MCRPC) patients treated with radium-223

Matteo Bauckneht, Selene Capitanio, Maria Isabella Donegani, Elisa Zanardi, Alberto Miceli, Roberto Murialdo, Stefano Raffa, Laura Tomasello, Martina Vitti, Alessia Cavo, Fabio Catalano, Manlio Mencoboni, Marcello Ceppi, Cecilia Marini, Giuseppe Fornarini, Francesco Boccardo, Gianmario Sambuceti, Silvia Morbelli

Research output: Contribution to journalArticle

Abstract

Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of reliable biomarkers to non-invasively determine its efficacy (possibly improving patients’ selection or identifying responders’ after therapy completion). 18F-Fluorodeoxyglucose (FDG)-avidity is low in naïve prostate cancer, but it is enhanced in advanced and chemotherapy-refractory mCRPC, providing prognostic insights. Moreover, this tool showed high potential for the evaluation of response in cancer patients with bone involvement. For these reasons, FDG Positron Emission Tomography (FDG-PET) might represent an effective tool that is able to provide prognostic stratification (improving patients selection) at baseline and assessing the treatment response to Ra223. We conducted a retrospective analysis of 28 mCRPC patients that were treated with Ra223 and submitted to bone scan and FDG-PET/CT for prognostic purposes at baseline and within two months after therapy completion. The following parameters were measured: number of bone lesions at bone scan, SUVmax of the hottest bone lesion, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). In patients who underwent post-therapy 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), (20/28), PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria were applied to evaluate the metabolic treatment response. The difference between end of therapy and baseline values was also calculated for Metabolic Tumor Volume (MTV), TLG, prostate-specific antigen (PSA), alkaline phosphatase (AP), and lactate dehydrogenase (LDH) (termed deltaMTV, deltaTLG, deltaPSA, deltaAP and deltaLDH, respectively). Predictive power of baseline and post-therapy PETand biochemical-derived parameters on OS were assessed by Kaplan–Meier, univariate and multivariate analyses. At baseline, PSA, LDH, and MTV significantly predicted OS. However, MTV (but not PSA nor LDH) was able to identify a subgroup of patients with worse prognosis, even after adjusting for the number of lesions at bone scan (which, in turn, was not an independent predictor of OS). After therapy, PERCIST criteria were able to capture the response to Ra223 by demonstrating longer OS in patients with partial metabolic response. Moreover, the biochemical parameters were outperformed by PERCIST in the post-treatment setting, as their variation after therapy was not informative on long term OS. The present study supports the role of FDG-PET as a tool for patient’s selection and response assessment in mCRPC patients undergoing Ra223 administration.

Original languageEnglish
Article number31
JournalCancers
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Radium
Castration
Fluorodeoxyglucose F18
Prostatic Neoplasms
Bone and Bones
Tumor Burden
Survival
Therapeutics
Prostate-Specific Antigen
L-Lactate Dehydrogenase
Patient Selection
Glycolysis
Neoplasms
Positron-Emission Tomography
Alkaline Phosphatase
Multivariate Analysis
Biomarkers

Keywords

  • Castrate resistant prostate cancer
  • FDG
  • Positron emission tomography
  • Radium-223

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (MCRPC) patients treated with radium-223. / Bauckneht, Matteo; Capitanio, Selene; Donegani, Maria Isabella; Zanardi, Elisa; Miceli, Alberto; Murialdo, Roberto; Raffa, Stefano; Tomasello, Laura; Vitti, Martina; Cavo, Alessia; Catalano, Fabio; Mencoboni, Manlio; Ceppi, Marcello; Marini, Cecilia; Fornarini, Giuseppe; Boccardo, Francesco; Sambuceti, Gianmario; Morbelli, Silvia.

In: Cancers, Vol. 12, No. 1, 31, 01.2020.

Research output: Contribution to journalArticle

Bauckneht, Matteo ; Capitanio, Selene ; Donegani, Maria Isabella ; Zanardi, Elisa ; Miceli, Alberto ; Murialdo, Roberto ; Raffa, Stefano ; Tomasello, Laura ; Vitti, Martina ; Cavo, Alessia ; Catalano, Fabio ; Mencoboni, Manlio ; Ceppi, Marcello ; Marini, Cecilia ; Fornarini, Giuseppe ; Boccardo, Francesco ; Sambuceti, Gianmario ; Morbelli, Silvia. / Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (MCRPC) patients treated with radium-223. In: Cancers. 2020 ; Vol. 12, No. 1.
@article{4fe0d81638b04b48b2e6e860f7fc3e62,
title = "Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (MCRPC) patients treated with radium-223",
abstract = "Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of reliable biomarkers to non-invasively determine its efficacy (possibly improving patients’ selection or identifying responders’ after therapy completion). 18F-Fluorodeoxyglucose (FDG)-avidity is low in na{\"i}ve prostate cancer, but it is enhanced in advanced and chemotherapy-refractory mCRPC, providing prognostic insights. Moreover, this tool showed high potential for the evaluation of response in cancer patients with bone involvement. For these reasons, FDG Positron Emission Tomography (FDG-PET) might represent an effective tool that is able to provide prognostic stratification (improving patients selection) at baseline and assessing the treatment response to Ra223. We conducted a retrospective analysis of 28 mCRPC patients that were treated with Ra223 and submitted to bone scan and FDG-PET/CT for prognostic purposes at baseline and within two months after therapy completion. The following parameters were measured: number of bone lesions at bone scan, SUVmax of the hottest bone lesion, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). In patients who underwent post-therapy 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), (20/28), PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria were applied to evaluate the metabolic treatment response. The difference between end of therapy and baseline values was also calculated for Metabolic Tumor Volume (MTV), TLG, prostate-specific antigen (PSA), alkaline phosphatase (AP), and lactate dehydrogenase (LDH) (termed deltaMTV, deltaTLG, deltaPSA, deltaAP and deltaLDH, respectively). Predictive power of baseline and post-therapy PETand biochemical-derived parameters on OS were assessed by Kaplan–Meier, univariate and multivariate analyses. At baseline, PSA, LDH, and MTV significantly predicted OS. However, MTV (but not PSA nor LDH) was able to identify a subgroup of patients with worse prognosis, even after adjusting for the number of lesions at bone scan (which, in turn, was not an independent predictor of OS). After therapy, PERCIST criteria were able to capture the response to Ra223 by demonstrating longer OS in patients with partial metabolic response. Moreover, the biochemical parameters were outperformed by PERCIST in the post-treatment setting, as their variation after therapy was not informative on long term OS. The present study supports the role of FDG-PET as a tool for patient’s selection and response assessment in mCRPC patients undergoing Ra223 administration.",
keywords = "Castrate resistant prostate cancer, FDG, Positron emission tomography, Radium-223",
author = "Matteo Bauckneht and Selene Capitanio and Donegani, {Maria Isabella} and Elisa Zanardi and Alberto Miceli and Roberto Murialdo and Stefano Raffa and Laura Tomasello and Martina Vitti and Alessia Cavo and Fabio Catalano and Manlio Mencoboni and Marcello Ceppi and Cecilia Marini and Giuseppe Fornarini and Francesco Boccardo and Gianmario Sambuceti and Silvia Morbelli",
year = "2020",
month = "1",
doi = "10.3390/cancers12010031",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (MCRPC) patients treated with radium-223

AU - Bauckneht, Matteo

AU - Capitanio, Selene

AU - Donegani, Maria Isabella

AU - Zanardi, Elisa

AU - Miceli, Alberto

AU - Murialdo, Roberto

AU - Raffa, Stefano

AU - Tomasello, Laura

AU - Vitti, Martina

AU - Cavo, Alessia

AU - Catalano, Fabio

AU - Mencoboni, Manlio

AU - Ceppi, Marcello

AU - Marini, Cecilia

AU - Fornarini, Giuseppe

AU - Boccardo, Francesco

AU - Sambuceti, Gianmario

AU - Morbelli, Silvia

PY - 2020/1

Y1 - 2020/1

N2 - Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of reliable biomarkers to non-invasively determine its efficacy (possibly improving patients’ selection or identifying responders’ after therapy completion). 18F-Fluorodeoxyglucose (FDG)-avidity is low in naïve prostate cancer, but it is enhanced in advanced and chemotherapy-refractory mCRPC, providing prognostic insights. Moreover, this tool showed high potential for the evaluation of response in cancer patients with bone involvement. For these reasons, FDG Positron Emission Tomography (FDG-PET) might represent an effective tool that is able to provide prognostic stratification (improving patients selection) at baseline and assessing the treatment response to Ra223. We conducted a retrospective analysis of 28 mCRPC patients that were treated with Ra223 and submitted to bone scan and FDG-PET/CT for prognostic purposes at baseline and within two months after therapy completion. The following parameters were measured: number of bone lesions at bone scan, SUVmax of the hottest bone lesion, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). In patients who underwent post-therapy 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), (20/28), PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria were applied to evaluate the metabolic treatment response. The difference between end of therapy and baseline values was also calculated for Metabolic Tumor Volume (MTV), TLG, prostate-specific antigen (PSA), alkaline phosphatase (AP), and lactate dehydrogenase (LDH) (termed deltaMTV, deltaTLG, deltaPSA, deltaAP and deltaLDH, respectively). Predictive power of baseline and post-therapy PETand biochemical-derived parameters on OS were assessed by Kaplan–Meier, univariate and multivariate analyses. At baseline, PSA, LDH, and MTV significantly predicted OS. However, MTV (but not PSA nor LDH) was able to identify a subgroup of patients with worse prognosis, even after adjusting for the number of lesions at bone scan (which, in turn, was not an independent predictor of OS). After therapy, PERCIST criteria were able to capture the response to Ra223 by demonstrating longer OS in patients with partial metabolic response. Moreover, the biochemical parameters were outperformed by PERCIST in the post-treatment setting, as their variation after therapy was not informative on long term OS. The present study supports the role of FDG-PET as a tool for patient’s selection and response assessment in mCRPC patients undergoing Ra223 administration.

AB - Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of reliable biomarkers to non-invasively determine its efficacy (possibly improving patients’ selection or identifying responders’ after therapy completion). 18F-Fluorodeoxyglucose (FDG)-avidity is low in naïve prostate cancer, but it is enhanced in advanced and chemotherapy-refractory mCRPC, providing prognostic insights. Moreover, this tool showed high potential for the evaluation of response in cancer patients with bone involvement. For these reasons, FDG Positron Emission Tomography (FDG-PET) might represent an effective tool that is able to provide prognostic stratification (improving patients selection) at baseline and assessing the treatment response to Ra223. We conducted a retrospective analysis of 28 mCRPC patients that were treated with Ra223 and submitted to bone scan and FDG-PET/CT for prognostic purposes at baseline and within two months after therapy completion. The following parameters were measured: number of bone lesions at bone scan, SUVmax of the hottest bone lesion, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). In patients who underwent post-therapy 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), (20/28), PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria were applied to evaluate the metabolic treatment response. The difference between end of therapy and baseline values was also calculated for Metabolic Tumor Volume (MTV), TLG, prostate-specific antigen (PSA), alkaline phosphatase (AP), and lactate dehydrogenase (LDH) (termed deltaMTV, deltaTLG, deltaPSA, deltaAP and deltaLDH, respectively). Predictive power of baseline and post-therapy PETand biochemical-derived parameters on OS were assessed by Kaplan–Meier, univariate and multivariate analyses. At baseline, PSA, LDH, and MTV significantly predicted OS. However, MTV (but not PSA nor LDH) was able to identify a subgroup of patients with worse prognosis, even after adjusting for the number of lesions at bone scan (which, in turn, was not an independent predictor of OS). After therapy, PERCIST criteria were able to capture the response to Ra223 by demonstrating longer OS in patients with partial metabolic response. Moreover, the biochemical parameters were outperformed by PERCIST in the post-treatment setting, as their variation after therapy was not informative on long term OS. The present study supports the role of FDG-PET as a tool for patient’s selection and response assessment in mCRPC patients undergoing Ra223 administration.

KW - Castrate resistant prostate cancer

KW - FDG

KW - Positron emission tomography

KW - Radium-223

UR - http://www.scopus.com/inward/record.url?scp=85077180146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077180146&partnerID=8YFLogxK

U2 - 10.3390/cancers12010031

DO - 10.3390/cancers12010031

M3 - Article

AN - SCOPUS:85077180146

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 31

ER -